Tobramycin: clinical and microbiological evaluation.
D000368:Aged; D000617:Aminoglycosides / Q000097:blood / Q000627:therapeutic use / Q000652:urine; D000900:Anti-Bacterial Agents / Q000097:blood / Q000627:therapeutic use* / Q000652:urine; D001168:Arthritis / Q000188:drug therapy; D001437:Bacteriuria / Q000188:drug therapy; D001660:Biliary Tract Diseases / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004341:Drug Evaluation; D004927:Escherichia coli Infections / Q000188:drug therapy; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011512:Proteus Infections / Q000188:drug therapy; D011552:Pseudomonas Infections / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D013203:Staphylococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy; D014946:Wound Infection / Q000188:drug therapy
D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D005839:Gentamicins